(Q58752199)

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Collagens: molecular biology, diseases, and potentials for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Genetic heterogeneity in osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

PPIB mutations cause severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Collagen prolyl 3-hydroxylation: a major role for a minor post-translational modification?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by TMEM38B mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Embryonic lethality of molecular chaperone hsp47 knockout mice is associated with defects in collagen biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Absence of FKBP10 in recessive type XI osteogenesis imperfecta leads to diminished collagen cross-linking and reduced collagen deposition in extracellular matrix.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Mutations in PLOD2 cause autosomal-recessive connective tissue disorders within the Bruck syndrome--osteogenesis imperfecta phenotypic spectrum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

A mutation in the 5'-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Osteogenesis imperfecta, an ever-expanding conundrum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Bril: a novel bone-specific modulator of mineralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Pigment epithelium-derived factor enhances differentiation and mineral deposition of human mesenchymal stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Deficiency for the ER-stress transducer OASIS causes severe recessive osteogenesis imperfecta in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Update on the evaluation and treatment of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Surgical treatment of osteogenesis imperfecta: current concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Operative treatment of severe scoliosis in osteogenesis imperfecta: results of 20 patients after halo traction and posterior spondylodesis with instrumentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Surgical treatment of scoliosis in osteogenesis imperfecta with cement-augmented pedicle screw instrumentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Primary and revision total hip arthroplasty in osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Bisphosphonates: how do they work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Bisphosphonate treatment in the oim mouse model alters bone modeling during growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Effects of the bisphosphonate risedronate on osteopenia in OASIS-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Intravenous neridronate in adults with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Effects of zoledronic acid in adults with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Evaluation of teriparatide treatment in adults with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Emerging therapeutic opportunities for skeletal restoration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

New drugs: Denosumab, dienogest/estradiol valerate, and polidocanol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Matrix-embedded cells control osteoclast formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Sclerostin: a gem from the genome leads to bone-building antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Distribution of single-cell expanded marrow derived progenitors in a developing mouse model of osteogenesis imperfecta following systemic transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Progenitors systemically transplanted into neonatal mice localize to areas of active bone formation in vivo: implications of cell therapy for skeletal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Amelioration of a mouse model of osteogenesis imperfecta with hematopoietic stem cell transplantation: microcomputed tomography studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Bone marrow stromal cells contribute to bone formation following infusion into femoral cavities of a mouse model of osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Local transplantation is an effective method for cell delivery in the osteogenesis imperfecta murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Fetal Mesenchymal Stem-Cell Engraftment in Bone after In Utero Transplantation in a Patient with Severe Osteogenesis Imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Partial rescue of a lethal phenotype of fragile bones in transgenic mice with a chimeric antisense gene directed against a mutated collagen gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Delivery of a hammerhead ribozyme specifically downregulates mutant type I collagen mRNA in a murine model of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

RNAi of COL1A1 in mesenchymal progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Allele dependent silencing of COL1A2 using small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Allele dependent silencing of collagen type I using small interfering RNAs targeting 3'UTR Indels - a novel therapeutic approach in osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Transfer of proalpha2(I) cDNA into cells of a murine model of human Osteogenesis Imperfecta restores synthesis of type I collagen comprised of alpha1(I) and alpha2(I) heterotrimers in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Gene targeting in stem cells from individuals with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197

Immature osteoblast lineage cells increase osteoclastogenesis in osteogenesis imperfecta murine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F21678707.2015.1006197